Table 2.
Clinical features of CD patients without DH.
| PT # | AGE | SEX | SERUM BIOMARKERS | HLA | MARSH | |
|---|---|---|---|---|---|---|
| Anti-TG2 (<9 neg 9-16 BL >16 pos) | Anti-TG3 (<16 neg 16-22 BL >22 pos) | |||||
| 1 | 21 | F | 101 | 8 | DQ2 - DR3 * | MARSH 3B |
| 2 | 42 | M | 81,4 | 10,7 | DQ2 - DR3 * | MARSH 2 |
| 3 | 70 | M | > 100 | 14,4 | DQ2 - DR3/DQ2 -DR7 | MARSH 3B |
| 4 | 41 | M | > 100 | 150 | DQ2 - DR3 * | MARSH 3C |
| 5 | 43 | M | 25,2 | 79,5 | DQ2 - DR3 * | MARSH 3B |
| 6 | 30 | M | 35,9 | 3,2 | DQ2 - DR3/DQ2 -DR7 | MARSH 3B |
| 7 | 45 | F | 94,5 | 25,6 | DQ2 - DR3/DQ8 - DR4 | MARSH 3B |
| 8 | 48 | F | > 100 | 6,6 | DQ2 - DR7* | MARSH 3B |
| 9 | 28 | M | 42,1 | 16,8 | DQ8 - DR4/DQ7 - DR11 | MARSH 3A |
| 10 | 21 | F | > 100 | 5,7 | ND | MARSH 3 B |
| 11 | 29 | F | 28* | 5,9 | DQ2 - DR7/DQ2 - DR7 | MARSH 3A |
| 12 | 17 | M | > 100 | 7,3 | DQ2 -DR3 * | MARSH 3C |
| 13 | 44 | F | 30,4 | 15,2 | DQ8 - DR4 * | MARSH 1 |
Anti-TG2, Anti-tissuetransglutaminase-IgA; Anti-TG3, Anti-epidermaltransglutaminase-IgA; HLA, Human Leukocyte Antigen; ND, Not done; * heterozygosis.